The NFO is available for subscription from January 16 to January 23. The schemes will list on BSE within 5 business days from the date of allotment.
Dr Reddy’s is amongst select companies in the world to have conducted a bioequivalence study and received tentative approval from the USFDA for palbociclib.
The inspection closed with issuance of a Form-483 with two observations.
Here are some stocks that may show significant price movement today.
Most Asian markets have started the day in Green today
The scheme aims for long-term capital appreciation by investing in equity & equity related instruments.
In conversation with Sheetal Agarwal of IIFL, company spokesperson discusses its strengths, opportunities and future outlook
In conversation with Sheetal Agarwal of IIFL, the founder provides insights about the company as well as potential of Blockchain technology
The latest IIP figure for November 2022 (IIP is announced with 1-month lag) marked a sharp turnaround in factory output growth.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
